The Lung Cancer Research Foundation (LCRF), in partnership with Boehringer Ingelheim, invites proposals for the 2025 Team Science Award to advance understanding and treatment of HER2-mutant lung cancer. This initiative funds multidisciplinary research teams focused on uncovering the biology, resistance mechanisms, and therapeutic innovations targeting HER2-driven malignancies. Projects must include studies involving patients with HER2-mutated lung cancer and incorporate both clinical and translational components.
Eligibility Criteria:
-
Applications must involve a team science approach with integrated projects addressing clinical, basic, or translational aspects of HER2-mutant lung cancer.
-
The proposal must include studies involving patients with HER2 mutations.
-
Applicants may submit only one LCRF grant application per cycle.
-
Principal investigators and collaborating institutions must demonstrate expertise relevant to lung cancer biology, molecular oncology, or therapeutic development.
-
Collaborative, multi-institutional teams are encouraged.
Funding Details:
-
Total award amount: 1,500,000 USD.
-
Duration: 3 years.
-
Funding supports clinical, basic, and translational research components.
- Projects may focus on:
-
Biology of HER2-mutant lung cancer.
-
Mechanisms of primary or secondary resistance to therapies.
-
Use of real-world data to analyze correlations between mutation status and demographics.
-
Tumor microenvironment and immune landscape.
-
Biomarker identification for predicting therapeutic response.
-
Optimization of HER2-targeted treatments.
-
Interaction between HER2 mutations, amplification, and overexpression.
-
Deadline:
-
Full proposal deadline: January 6, 2026.
-
Funding period: 3 years from award initiation.
Where to Go For Further Information: